Toggle Main Menu Toggle Search

Open Access padlockePrints

PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in Chronic Lymphocytic Leukaemia

Lookup NU author(s): Dr Ashleigh Herriott, Dr Susan Tudhope, Gesa Junge, Natalie Rodrigues, Dr Miranda Patterson, Dr Laura Woodhouse, Professor John LunecORCiD, Dr Jill Hunter, Dr Evan Mulligan, Mike Cole, Dr Jonathan Wallis, Professor Nicola CurtinORCiD, Dr Elaine WillmoreORCiD



This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Publication metadata

Author(s): Herriott A, Tudhope SJ, Junge G, Rodrigues N, Patternson MJ, Woodhouse L, Lunec J, Hunter JE, Mulligan EA, Cole M, Allinson LM, Wallis JP, Marshall S, Wang E, Curtin NJ, Willmore E

Publication type: Article

Publication status: Published

Journal: Oncotarget

Year: 2015

Volume: 6

Issue: 41

Pages: 43978-43991

Online publication date: 02/11/2015

Acceptance date: 10/10/2015

Date deposited: 18/11/2015

ISSN (electronic): 1949-2553

Publisher: Impact Journals, LLC


DOI: 10.18632/oncotarget.6287

PubMed id: 26539646


Altmetrics provided by Altmetric


Funder referenceFunder name
Tyneside Leukaemia Research Association (now part of Newcastle Healthcare Charity)
Medical Research Council/AstraZeneca
10035Leukaemia & Lymphoma Research
13034Leukaemia & Lymphoma Research
C7369/A8048Cancer Research UK
KKL409Kay Kendall Leukaemia Fund
10035Bloodwise (Formerly Leukaemia and Lymphoma Research)